These tumor infiltrating lymphocytes (TILs) include CD4 and CD8 T-cells and can be isolated from resected tumors, cultured and expanded in the presence of high-dose IL-2, and re-infused into patients after lymphodepleting chemotherapy. This evidence concerns the gene CD8A and neoplasm.